CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Impax Laboratories Inc. v. Lannett Holdings Inc.

1:14-cv-00984

Overview

Case Number 1:14-cv-00984
Filing Date 2014-07-25
Status Terminated
Termination Date 2017-04-17
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Lannett Company Inc. Operating Company

Represented By

1 Attorneys Listed

Austen C. Endersby

Fox Rothschild LLP

Tel: +1 (302) 654-7444

919 North Market Street, Suite 300, P.O. Box 2323

Lannett Holdings Inc. NPE (Patent Assertion Entity)

Represented By

1 Attorneys Listed

Austen C. Endersby

Fox Rothschild LLP

Tel: +1 (302) 654-7444

919 North Market Street, Suite 300, P.O. Box 2323

Plaintiff

AstraZeneca UK Limited NPE (University / Research)

Represented By

3 Attorneys Listed

Tiffany Geyer Lydon

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

AstraZeneca AB NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Tiffany Geyer Lydon

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Impax Laboratories Inc. Operating Company

Represented By

10 Attorneys Listed

Tiffany Geyer Lydon

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Stefan M. Miller

Email: stefan.miller@kirkland.com

Michael J. Flibbert

Email: michael.flibbert@finnegan.com

Marcus E. Sernel

Email: marc.sernel@kirkland.com

L. Scott Burwell

Email: scott.burwell@finnegan.com

Danielle A. Duszczyszyn

Email: Danielle.duszczyszyn@finnegan.com

Ashley L.B. Ross

Email: ashley.ross@kirkland.com

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Alyse Wu

Email: alyse.wu@kirkland.com

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Counter Defendant

Astrazeneca AB NPE (Individual / Inventor)

Represented By

3 Attorneys Listed

Tiffany Geyer Lydon

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Andrew Colin Mayo

Ashby & Geddes

Tel: +1 (302) 654-1888

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Steven J. Balick

Ashby & Geddes

Tel: +1 (302) 654-1888
Fax: +1 (302) 654-2067

Ashby & Geddes, 500 Delaware Avenue, 8th Floor

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 1 proceeding
🏛️
USPTO PTAB Trials 2 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (3 found):
PTAB: 2 U.S. Courts: 1
USPTO PTAB Trial 2015-07-28
IPR2015-01630

Lannett Holdings, Inc. v. AstraZeneca AB

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2015-07-28
IPR2015-01629

Lannett Holdings, Inc. v. AstraZeneca AB

U.S. Continuation Sibling (6750237)
Status: Institution Denied
U.S. District Court 2014-07-30
1:14-cv-00999

Impax Laboratories Inc. v. Lannett Holdings Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6750237
Pharmaceutical formulations containing zolmitriptan
Filed: 2000-11-28
Issued: 2004-06-15
Expired (Term Ended)
Expires: 2020-11-28
US7220767
Pharmaceutical formulations containing zolmitriptan
Filed: 2004-05-27
Issued: 2007-05-22
Expired (Term Ended)
Expires: 2024-05-27

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

22

Dispositive

5

Granted

1

Denied

0

Pending / Review

21

Motions by Category

Procedural / Extension Motion 4 Motion to Dismiss 5 Claim Construction / Markman Filing 13

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
MEMORANDUM ORDER Consolidating Cases and Denying Motion to Dismiss (see D.I. 9 in 14cv984-RGA). Signed by Judge Richard G. Andrews on 12/10/2014. Associated Cas...
Entry #33 • 2014-12-10 Document →
Motion to Dismiss Pending / Under Review
REPLY BRIEF re 9 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Lannett Company Inc., Lannett Holdings Inc.. (Niederman, Seth) (Ent...
Entry #19 • 2014-10-24 Document →
Motion to Dismiss Pending / Under Review
ANSWERING BRIEF in Opposition re 9 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by AstraZeneca AB, Impax Laboratories Inc..Reply Bri...
Entry #12 • 2014-10-14 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter - filed by Lannett Company Inc., Lannett Holdings Inc.. (Attachments: # 1 Proposed Order)(End...
Entry #9 • 2014-09-24 Document →
Motion to Dismiss Pending / Under Review
OPENING BRIEF in Support re 9 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Lannett Company Inc., Lannett Holdings Inc..Answering ...
Entry #10 • 2014-09-24 Document →
Claim Construction / Markman Filing Pending / Under Review
MEMORANDUM OPINION providing claim construction for disputed terms in U.S. Patent Nos. 6,750,237 and 7,220,767. Within five days the parties shall submit a pr...
Entry #60 • 2015-12-01 Document →

Docket Entries

(60 total)
Pleading / Complaint

COMPLAINT filed against Lannett Company Inc., Lannett Holdings Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 21760.) - filed by Impax Laboratories Inc., AstraZeneca AB. (Attachments: # 1 Exhibit A-B, # 2 Civil Cover Sheet, # 3 Acknowledgement of Consent Form)(snb, ) (Entered: 07/28/2014)

Entry #1 • 2014-07-25
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (snb, ) (Entered: 07/28/2014)

Entry #2 • 2014-07-25
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 6/16/2014. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 12/16/2016. (snb, ) (Entered: 07/28/2014)

Entry #3 • 2014-07-25
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,750,237 B2; 7,220,767 B2. (snb, ) (Entered: 07/28/2014)

Entry #4 • 2014-07-25
1
Pleading / Complaint

SUMMONS Returned Executed by Impax Laboratories Inc., AstraZeneca AB. Lannett Holdings Inc. served on 7/25/2014, answer due 8/15/2014. (Mayo, Andrew) (Entered: 07/29/2014)

Entry #5 • 2014-07-29
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc